EnteroBiotix has announced it has secured £19 million ($26 million) in financing to advance a treatment for irritable bowel syndrome. The biopharmaceutical company is set to use the investment to advance its lead candidate, EBX-102-02, a next-generation orally delivered full-spectrum investigational microbiome therapeutic. EBX-102-02 will be advanced into Phase… Read More
EnteroBiotix, a clinical-stage biopharmaceutical company developing best-in-class drugs for gut health, has announced positive initial results with EBX-102-02, the company’s next-generation full-spectrum microbiome product, from the TrIuMPH Phase IIa clinical trial in adults with irritable bowel syndrome with constipation (IBS-C). The multicentre, randomised, double-blind, placebo-controlled TrIuMPH (Treating IBS with an… Read More
EnteroBiotix, a Glasgow, UK based biotechnology company, has dosed the first patient in a clinical trial designed to evaluate EBX-102-02 for the treatment of irritable bowel syndrome (IBS). The Phase II study, named ‘TrIuMPH’ (treating IBS with an intestinal microbiota product for health) will initially enrol… Read More
